search
Back to results

Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment

Primary Purpose

Healthy, Hepatic Impairment

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Favipiravir
Favipiravir
Favipiravir
Sponsored by
MDVI, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Healthy focused on measuring Healthy, hepatic impairment, T-705a, Favipiravir

Eligibility Criteria

19 Years - 69 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Hepatically impaired groups:

    • Agree to doctor approved birth control methods from Day 1 until 3 months following the final dose of study drug.
    • Have mild hepatic impairment (Child-Pugh Clinical Assessment Score Grade A, score 5 6) or moderate hepatic impairment (Child-Pugh Clinical Assessment Score Grade B, score 7-9) or severe hepatic impairment (Child-Pugh Clinical Assessment Score Grade C, score 10-15);
  • Control group

    • Agree to doctor approved birth control methods from Day 1 until 3 months following the final dose of study drug.
    • Healthy as determined by medical history, physical exam, vital signs, ECGs, and clinical laboratory tests.

Exclusion Criteria:

  • Hepatically impaired groups:

    • Have used any drugs known to significantly affect hepatic metabolism within 28 days, or is unable or unwilling to forgo the use of such products throughout the study;
    • Have any acute or unstable condition or disease, other than impaired hepatic function, as determined by medical history, physical exam, ECG and clinical laboratory tests;
    • Known ongoing alcohol and/or drug abuse within 1 month
    • Any evidence of progressive worsening liver function disease as indicated by laboratory values;
    • Have had an acute flare of hepatitis A or B within 6 months;
    • Have acute, fulminant alcoholic hepatitis, determined either clinically or by histology;
    • Have a history of hepatoma or metastatic disease of the liver;
  • Control group:

    • Have used any drugs known to significantly affect hepatic metabolism within 28 days, or is unable or unwilling to forgo the use of such products throughout the study;
    • Have a history or presence of clinically cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, hepatic, immunologic, neurologic, oncologic, psychiatric, pulmonary, or renal disease or any other condition.

Sites / Locations

  • University of Miami
  • Orlando Clinical Research Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Group 1

Group 2

Group 3

Group 4

Arm Description

Normal hepatic function

Mild hepatic impairment

Moderate hepatic impairment

Severe hepatic impairment

Outcomes

Primary Outcome Measures

Cmax of favipiravir
The PK parameters for favipiravir and its metabolite in hepatically impaired adult subjects relative to healthy adult subjects matched for age, weight, gender, and race status on Day 1 and on Day 5.
AUC of favipiravir
The PK parameters for favipiravir and its metabolite in hepatically impaired adult subjects relative to healthy adult subjects matched for age, weight, gender, and race status on Day 1 and on Day 5.

Secondary Outcome Measures

vital signs
electrocardiograms [ECGs]
clinical laboratory assessment
adverse events [AEs]
physical examination

Full Information

First Posted
August 10, 2011
Last Updated
October 20, 2015
Sponsor
MDVI, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT01419457
Brief Title
Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment
Official Title
A Phase I, Open-Label, Parallel-Group, Multiple-Dose Study to Determine the Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment and in Healthy Control Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
October 2015
Overall Recruitment Status
Completed
Study Start Date
August 2011 (undefined)
Primary Completion Date
February 2013 (Actual)
Study Completion Date
February 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MDVI, LLC

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is designed to determine the pharmacokinetics of favipiravir in volunteers with hepatic impairment and in healthy control volunteers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy, Hepatic Impairment
Keywords
Healthy, hepatic impairment, T-705a, Favipiravir

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1
Arm Type
Experimental
Arm Description
Normal hepatic function
Arm Title
Group 2
Arm Type
Experimental
Arm Description
Mild hepatic impairment
Arm Title
Group 3
Arm Type
Experimental
Arm Description
Moderate hepatic impairment
Arm Title
Group 4
Arm Type
Experimental
Arm Description
Severe hepatic impairment
Intervention Type
Drug
Intervention Name(s)
Favipiravir
Other Intervention Name(s)
T-705a
Intervention Description
1200 mg BID for Day 1 + 800 mg BID for Day 2-5
Intervention Type
Drug
Intervention Name(s)
Favipiravir
Other Intervention Name(s)
T-705a
Intervention Description
800 mg BID for Day 1 + 400 mg BID for Day 2-3
Intervention Type
Drug
Intervention Name(s)
Favipiravir
Intervention Description
800 mg Single Dose
Primary Outcome Measure Information:
Title
Cmax of favipiravir
Description
The PK parameters for favipiravir and its metabolite in hepatically impaired adult subjects relative to healthy adult subjects matched for age, weight, gender, and race status on Day 1 and on Day 5.
Time Frame
predose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 18, 24, 36, 48 hours post-dose on Day 1 and Day 5
Title
AUC of favipiravir
Description
The PK parameters for favipiravir and its metabolite in hepatically impaired adult subjects relative to healthy adult subjects matched for age, weight, gender, and race status on Day 1 and on Day 5.
Time Frame
predose and 0.25, 0.5, 0.75, 1, 2, 4, 6, 12, 18, 24, 36, 48 hours post-dose on Day 1 and Day 5
Secondary Outcome Measure Information:
Title
vital signs
Time Frame
13 days
Title
electrocardiograms [ECGs]
Time Frame
13 days
Title
clinical laboratory assessment
Time Frame
13 days
Title
adverse events [AEs]
Time Frame
13 days
Title
physical examination
Time Frame
13 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Hepatically impaired groups: Agree to doctor approved birth control methods from Day 1 until 3 months following the final dose of study drug. Have mild hepatic impairment (Child-Pugh Clinical Assessment Score Grade A, score 5 6) or moderate hepatic impairment (Child-Pugh Clinical Assessment Score Grade B, score 7-9) or severe hepatic impairment (Child-Pugh Clinical Assessment Score Grade C, score 10-15); Control group Agree to doctor approved birth control methods from Day 1 until 3 months following the final dose of study drug. Healthy as determined by medical history, physical exam, vital signs, ECGs, and clinical laboratory tests. Exclusion Criteria: Hepatically impaired groups: Have used any drugs known to significantly affect hepatic metabolism within 28 days, or is unable or unwilling to forgo the use of such products throughout the study; Have any acute or unstable condition or disease, other than impaired hepatic function, as determined by medical history, physical exam, ECG and clinical laboratory tests; Known ongoing alcohol and/or drug abuse within 1 month Any evidence of progressive worsening liver function disease as indicated by laboratory values; Have had an acute flare of hepatitis A or B within 6 months; Have acute, fulminant alcoholic hepatitis, determined either clinically or by histology; Have a history of hepatoma or metastatic disease of the liver; Control group: Have used any drugs known to significantly affect hepatic metabolism within 28 days, or is unable or unwilling to forgo the use of such products throughout the study; Have a history or presence of clinically cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, hepatic, immunologic, neurologic, oncologic, psychiatric, pulmonary, or renal disease or any other condition.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard A. Preston, MD/MSHP/MBA
Organizational Affiliation
University of Miami
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Miami
City
Miami
State/Province
Florida
Country
United States
Facility Name
Orlando Clinical Research Center
City
Orlando
State/Province
Florida
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment

We'll reach out to this number within 24 hrs